DR. REDDY'S LABORATORIES-ADR (RDY) Fundamental Analysis & Valuation

NYSE:RDY • US2561352038

Current stock price

14.095 USD
+0.13 (+0.89%)
Last:

This RDY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. RDY Profitability Analysis

1.1 Basic Checks

  • RDY had positive earnings in the past year.
  • In the past year RDY had a positive cash flow from operations.
  • RDY had positive earnings in each of the past 5 years.
  • Each year in the past 5 years RDY had a positive operating cash flow.
RDY Yearly Net Income VS EBIT VS OCF VS FCFRDY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B 60B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 10.62%, RDY belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • The Return On Equity of RDY (16.03%) is better than 88.48% of its industry peers.
  • The Return On Invested Capital of RDY (13.03%) is better than 91.62% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RDY is above the industry average of 13.10%.
Industry RankSector Rank
ROA 10.62%
ROE 16.03%
ROIC 13.03%
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
RDY Yearly ROA, ROE, ROICRDY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 16.82%, RDY belongs to the best of the industry, outperforming 89.01% of the companies in the same industry.
  • RDY's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 19.62%, RDY belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
  • In the last couple of years the Operating Margin of RDY has grown nicely.
  • RDY has a better Gross Margin (66.88%) than 74.35% of its industry peers.
  • RDY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.62%
PM (TTM) 16.82%
GM 66.88%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
RDY Yearly Profit, Operating, Gross MarginsRDY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. RDY Health Analysis

2.1 Basic Checks

  • RDY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for RDY remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for RDY has been increased compared to 5 years ago.
  • Compared to 1 year ago, RDY has a worse debt to assets ratio.
RDY Yearly Shares OutstandingRDY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
RDY Yearly Total Debt VS Total AssetsRDY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B

2.2 Solvency

  • RDY has an Altman-Z score of 5.83. This indicates that RDY is financially healthy and has little risk of bankruptcy at the moment.
  • RDY has a better Altman-Z score (5.83) than 76.44% of its industry peers.
  • RDY has a debt to FCF ratio of 3.17. This is a good value and a sign of high solvency as RDY would need 3.17 years to pay back of all of its debts.
  • RDY has a better Debt to FCF ratio (3.17) than 90.05% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that RDY is not too dependend on debt financing.
  • RDY has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 3.17
Altman-Z 5.83
ROIC/WACC1.28
WACC10.21%
RDY Yearly LT Debt VS Equity VS FCFRDY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100B 200B 300B

2.3 Liquidity

  • RDY has a Current Ratio of 1.85. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
  • RDY's Current ratio of 1.85 is on the low side compared to the rest of the industry. RDY is outperformed by 68.59% of its industry peers.
  • RDY has a Quick Ratio of 1.35. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.35, RDY is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
  • The current and quick ratio evaluation for RDY is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.35
RDY Yearly Current Assets VS Current LiabilitesRDY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B 250B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. RDY Growth Analysis

3.1 Past

  • RDY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.81%.
  • The Earnings Per Share has been growing by 23.62% on average over the past years. This is a very strong growth
  • Looking at the last year, RDY shows a quite strong growth in Revenue. The Revenue has grown by 11.06% in the last year.
  • Measured over the past years, RDY shows a quite strong growth in Revenue. The Revenue has been growing by 13.26% on average per year.
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.17% on average over the next years.
  • Based on estimates for the next years, RDY will show a small growth in Revenue. The Revenue will grow by 7.09% on average per year.
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RDY Yearly Revenue VS EstimatesRDY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100B 200B 300B 400B
RDY Yearly EPS VS EstimatesRDY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20 40 60

More info and screens

Find the best growth stocksShow best growing peers

5

4. RDY Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 19.85 indicates a rather expensive valuation of RDY.
  • 83.77% of the companies in the same industry are more expensive than RDY, based on the Price/Earnings ratio.
  • RDY is valuated rather cheaply when we compare the Price/Earnings ratio to 27.15, which is the current average of the S&P500 Index.
  • RDY is valuated rather expensively with a Price/Forward Earnings ratio of 23.62.
  • 77.49% of the companies in the same industry are more expensive than RDY, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.12. RDY is around the same levels.
Industry RankSector Rank
PE 19.85
Fwd PE 23.62
RDY Price Earnings VS Forward Price EarningsRDY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RDY is valued cheaply inside the industry as 85.34% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RDY indicates a somewhat cheap valuation: RDY is cheaper than 77.49% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 59.85
EV/EBITDA 11.76
RDY Per share dataRDY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • RDY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.84
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. RDY Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.60%, RDY is not a good candidate for dividend investing.
  • RDY's Dividend Yield is rather good when compared to the industry average which is at 0.73. RDY pays more dividend than 89.01% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, RDY's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.6%

5.2 History

  • The dividend of RDY decreases each year by -19.44%.
  • RDY has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-19.44%
Div Incr Years0
Div Non Decr Years0
RDY Yearly Dividends per shareRDY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

5.3 Sustainability

  • RDY pays out 11.54% of its income as dividend. This is a sustainable payout ratio.
  • RDY's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP11.54%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
RDY Yearly Income VS Free CF VS DividendRDY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B
RDY Dividend Payout.RDY Dividend Payout, showing the Payout Ratio.RDY Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RDY Fundamentals: All Metrics, Ratios and Statistics

DR. REDDY'S LABORATORIES-ADR

NYSE:RDY (4/28/2026, 9:58:45 AM)

14.095

+0.13 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)05-12
Inst Owners52.17%
Inst Owner Change4.02%
Ins Owners1.23%
Ins Owner Change0%
Market Cap11.74B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Analysts67.56
Price Target14.57 (3.37%)
Short Float %2.25%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield 0.6%
Yearly Dividend0.08
Dividend Growth(5Y)-19.44%
DP11.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.63%
Min EPS beat(2)-8.52%
Max EPS beat(2)-6.74%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-8.52%
Max EPS beat(4)2.77%
EPS beat(8)4
Avg EPS beat(8)-0.94%
EPS beat(12)8
Avg EPS beat(12)6.66%
EPS beat(16)10
Avg EPS beat(16)7.01%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-1.51%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)1%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)7
Avg Revenue beat(12)1.24%
Revenue beat(16)9
Avg Revenue beat(16)1.2%
PT rev (1m)-4.38%
PT rev (3m)-2.35%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.52%
Valuation
Industry RankSector Rank
PE 19.85
Fwd PE 23.62
P/S 3.22
P/FCF 59.85
P/OCF 18.79
P/B 3.07
P/tB 4.51
EV/EBITDA 11.76
EPS(TTM)0.71
EY5.04%
EPS(NY)0.6
Fwd EY4.23%
FCF(TTM)0.24
FCFY1.67%
OCF(TTM)0.75
OCFY5.32%
SpS4.37
BVpS4.59
TBVpS3.13
PEG (NY)N/A
PEG (5Y)0.84
Graham Number8.56477 (-39.24%)
Profitability
Industry RankSector Rank
ROA 10.62%
ROE 16.03%
ROCE 17.14%
ROIC 13.03%
ROICexc 16.05%
ROICexgc 25.11%
OM 19.62%
PM (TTM) 16.82%
GM 66.88%
FCFM 5.38%
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
ROICexc(3y)19.62%
ROICexc(5y)17.62%
ROICexgc(3y)25.36%
ROICexgc(5y)22.59%
ROCE(3y)21.22%
ROCE(5y)19.86%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y2.58%
ROICexc growth 3Y0.6%
ROICexc growth 5Y-0.12%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 3.17
Debt/EBITDA 0.13
Cap/Depr 211.61%
Cap/Sales 11.76%
Interest Coverage 16.55
Cash Conversion 68.09%
Profit Quality 32%
Current Ratio 1.85
Quick Ratio 1.35
Altman-Z 5.83
F-Score4
WACC10.21%
ROIC/WACC1.28
Cap/Depr(3y)179.81%
Cap/Depr(5y)161.03%
Cap/Sales(3y)9.33%
Cap/Sales(5y)8.68%
Profit Quality(3y)47.43%
Profit Quality(5y)60.48%
High Growth Momentum
Growth
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%
EBIT growth 1Y1.53%
EBIT growth 3Y25.68%
EBIT growth 5Y18.58%
EBIT Next Year11.24%
EBIT Next 3Y7.07%
EBIT Next 5Y9.87%
FCF growth 1Y-62.42%
FCF growth 3Y9.92%
FCF growth 5Y-12.7%
OCF growth 1Y-18.43%
OCF growth 3Y18.21%
OCF growth 5Y9.24%

DR. REDDY'S LABORATORIES-ADR / RDY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DR. REDDY'S LABORATORIES-ADR (RDY) stock?

ChartMill assigns a fundamental rating of 6 / 10 to RDY.


What is the valuation status for RDY stock?

ChartMill assigns a valuation rating of 5 / 10 to DR. REDDY'S LABORATORIES-ADR (RDY). This can be considered as Fairly Valued.


How profitable is DR. REDDY'S LABORATORIES-ADR (RDY) stock?

DR. REDDY'S LABORATORIES-ADR (RDY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of DR. REDDY'S LABORATORIES-ADR (RDY) stock?

The Price/Earnings (PE) ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 19.85 and the Price/Book (PB) ratio is 3.07.


How financially healthy is DR. REDDY'S LABORATORIES-ADR?

The financial health rating of DR. REDDY'S LABORATORIES-ADR (RDY) is 6 / 10.